Which adenomas are detected by fecal occult blood testing? A state-wide analysis from Bavaria, Germany

International Journal of Cancer

Volumn 136, Issue 7, 2015, Pages 1672-1679

  Brenner, Hermann ^a   Hoffmeister, Michael ^a   Birkner, Berndt ^b,c   Stock, Christian ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Gastroenterological Practice   (Germany)

^c Association of Statutory Health Insurance Physicians Bavaria   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adenoma; Colonoscopy; Colorectal neoplasia; Fecal occult blood tests

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; FEMALE; FOLLOW UP; GERMANY; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCCULT BLOOD; ONCOLOGICAL PARAMETERS; SEX DIFFERENCE; TUMOR LOCALIZATION; TUMOR NUMBER; TUMOR SHAPE; TUMOR VOLUME; ADENOMA; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; FACTUAL DATABASE; MASS SCREENING; RISK;

ADENOMA; AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; EARLY DETECTION OF CANCER; FEMALE; GERMANY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; ODDS RATIO; TUMOR BURDEN;

EID: 84920927720     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29148     Document Type: Article

References (32)

1. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541-9.
2. Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012;61:1036-40.
3. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-14.
4. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population of average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-25.
5. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012;26:131-47.
6. Imperiale TF. Noninvasive screening tests for colorectal cancer. Dig Dis 2012;30 (Suppl 2):16-26.
7. Brenner H, Tao S. Superior diagnostic performance of fecal immunochemical tests for hemoglobin in a head-to-head comparison with guaiac based fecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013;49:3049-54.
8. Brenner H, Hoffmeister M, Birkner B, et al. Diagnostic performance of guaiac based fecal occult blood test in routine screening: state-wide analysis from Bavaria, Germany. Am J Gastroenterol 2014;109;427-35.
9. Pox CP, Altenhofen L, Brenner H, et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012;142:1460-7.
10. Adler A, Lieberman D, Aminalai A, et al. Data quality of the German screening colonoscopy registry. Endoscopy 2013;45:813-8.
11. Mansmann U, Crispin A, Henschel V, et al. Epidemiology and quality control of 245 000 outpatient colonoscopies. Dtsch Arztebl Int 2008;105:434-40.
12. Crispin A, Birkner B, Munte A, et al. Process quality and incidence of acute complications in a series of more than 230,000 outpatient colonoscopies. Endoscopy 2009;41:1018-25.
13. Kolligs FT, Crispin A, Munte A, et al. Risk of advanced colorectal neoplasia according to age and gender. PLoS One 2011;6:e20076.
14. Stock C, Hoffmeister M, Birkner B, et al. Utilization and yield of neoplasms in colonoscopies performed within 3 years after screening colonoscopy: a historical cohort study. Endoscopy 2013;45:537-46.
15. Crispin A, Mansmann U, Munte A, et al. A direct comparison of the prevalence of advanced adenoma and cancer between surveillance and screening colonoscopies. Digestion 2013;87:170-5.
16. Brenner H, Hoffmeister M, Birkner B, et al. Men with negative results of guaiac based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results. Int J Cancer 2014;134:2927-34.
17. Qaseem A, Denberg TD, Hopkins RH, Jr, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012;156:378-86.
18. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013. Available at: URL http://www.R-project.org/.
19. Haug U, Knudsen A, Brenner H, et al. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn 2011;11:605-16.
20. Logan RF, Patnick J, Nickerson C, et al. English bowel cancer screening evaluation committee. Outcomes of the bowel cancer screening programme (BCSP) in England after the first million tests. Gut 2012;61:1439-46.
21. Nakama H, Zhang B, Kamijo N. Sensitivity of immunochemical fecal occult blood test for colorectal flat adenomas. Hepatogastroenterology 2004;51:1333-6.
22. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162-9.
23. Rozen P, Levi Z, Hazazi R, et al. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009;29:906-17.
24. Haug U, Kuntz KM, Knudsen AB, et al. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011;104:1779-85.
25. Steele RJ, McClemments P, Watling C, et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012;61:576-81.
26. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-69.
27. Corley DA, Jensen CD, Marks AR, et al. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol 2013;11:172-80.
28. Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005;352:2061-8.
29. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010;105:2457-64.
30. Massat NJ, Moss SM, Halloran SP, et al. Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences. J Med Screen 2013;20:125-48.
31. van Rijn AF, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343-50.
32. Heresbach D, Barrioz T, Lapalus MG, et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 2008;40:284-90.